Biodesix (NASDAQ:BDSX – Get Free Report) was upgraded by equities researchers at HC Wainwright to a “strong-buy” rating in a report released on Monday,Zacks.com reports.
BDSX has been the topic of several other research reports. Weiss Ratings raised Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Canaccord Genuity Group boosted their price target on shares of Biodesix from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Finally, William Blair upgraded shares of Biodesix from a “market perform” rating to an “outperform” rating in a report on Friday, February 27th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Biodesix has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.
Read Our Latest Analysis on Biodesix
Biodesix Trading Up 3.6%
Biodesix (NASDAQ:BDSX – Get Free Report) last posted its earnings results on Monday, May 4th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($1.13) by $0.32. The firm had revenue of $25.56 million for the quarter, compared to analysts’ expectations of $23.12 million. Biodesix had a negative net margin of 33.26% and a negative return on equity of 2,101.40%. Research analysts anticipate that Biodesix will post -2.99 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in BDSX. Aberdeen Group plc purchased a new stake in Biodesix in the 4th quarter worth about $1,784,000. Oracle Investment Management Inc. bought a new position in Biodesix during the third quarter worth about $113,000. Renaissance Technologies LLC purchased a new position in shares of Biodesix in the first quarter worth about $173,000. Sei Investments Co. bought a new stake in shares of Biodesix in the first quarter valued at approximately $624,000. Finally, Cetera Investment Advisers lifted its stake in shares of Biodesix by 20.0% during the 1st quarter. Cetera Investment Advisers now owns 12,000 shares of the company’s stock valued at $174,000 after buying an additional 2,000 shares in the last quarter. Institutional investors own 20.96% of the company’s stock.
Biodesix Company Profile
Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.
The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.
Recommended Stories
- Five stocks we like better than Biodesix
- 3 AI Stocks With Moats That Could Outlast Summer Volatility
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
Receive News & Ratings for Biodesix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodesix and related companies with MarketBeat.com's FREE daily email newsletter.
